Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.49
- Piotroski Score 8.00
- Grade Overweight
- Symbol (MRK)
- Company Merck & Co., Inc.
- Price $115.85
- Changes Percentage (0.52%)
- Change $0.6
- Day Low $115.00
- Day High $116.76
- Year High $134.63
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
- Last Earnings 07/23/2024
- Ex-Dividend for 5/16 Dividend 09/16/2024
- Dividend Payable 10/07/2024
- Today N/A
- Next Earnings (Estimated) 10/31/2024
- Fiscal Year End N/A
- Average Stock Price Target $120.00
- High Stock Price Target $294.00
- Low Stock Price Target $80.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.91
- Trailing P/E Ratio 143.59
- Forward P/E Ratio 143.59
- P/E Growth 143.59
- Net Income $365.00 M
Income Statement
Quarterly
Annual
Latest News of MRK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Merck & Co. (MRK) the Best Blue Chip Stock To Invest In According to Short Sellers?
Discover the top 12 blue-chip stocks favored by short sellers, including Merck & Co., Inc. Analysis by financial experts reveals insights on market trends, economic conditions, and investment strategi...
By Yahoo! Finance | 1 day ago -
Merck & Co., Inc. (MRK): A Good Beginner Stock According to Analysts
Insider Monkey compiled the 7 Best Stocks for Beginners with Little Money. Merck & Co., Inc. (MRK) is analyzed against other beginner stocks. Analysts have varying views on market conditions, caution ...
By Yahoo! Finance | 1 day ago -
Is Merck & Co., Inc. (MRK) the Best Defensive Stock According to Reddit?
The article discusses the defensive stock Merck & Co., Inc. (NYSE:MRK) and its performance against other stocks. It also highlights expert opinions on market conditions and investment strategies amids...
By Yahoo! Finance | 3 days ago
